Intranasal TIDM peptide for tauopathy
用于治疗 tau 蛋白病的鼻内 TIDM 肽
基本信息
- 批准号:10274908
- 负责人:
- 金额:$ 15.7万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-15 至 2022-08-31
- 项目状态:已结题
- 来源:
- 关键词:Administrative SupplementAlzheimer&aposs DiseaseApplications GrantsBacteriaBehaviorBindingBrainBrain InjuriesCognitiveDevelopmentEngineeringFlagellinFrontotemporal DementiaInflammationIntranasal AdministrationLinkMediatingMicrogliaMolecular TargetMonitorMusMutateNatural ImmunityNerve DegenerationNeurodegenerative DisordersNeurofibrillary TanglesNeuronsOutcomePathologicPathologyPathway interactionsPeptidesProgressive Supranuclear PalsyReportingRoleSpecificityTLR2 geneTauopathiesTestingTherapeuticToll-like receptorsTransgenic MiceViralVirusadaptive immunitybrain parenchymacell typeeffective therapyfamilial Alzheimer diseasehyperphosphorylated tauinhibitor/antagonistneuroinflammationnovelprospectivetau Proteinstau aggregationtau-1
项目摘要
Effective reduction of aggregated tau from the brain parenchyma is expected to reduce the development and
progression of both sporadic and familial Alzheimer’s disease (AD), progressive supranuclear palsy (PSP),
frontotemporal dementia (FTD), and other tauopathies. However, pathways for lowering aggregated tau from
the brain are poorly understood. Neuroinflammation is another hallmark of neurodegenerative disorders and
recently it has been shown that the progression of phospho-tau pathology is driven by microglia and that
microglial activation forms the crucial link between tau aggregation and brain damage. Here, we want to test
a novel hypothesis that intranasal administration of wild type TLR2-interacting domain of MyD88
(wtTIDM) peptide suppresses microglial inflammation and decreases tauopathy in P301S transgenic mice
via TLR2. A positive outcome of this grant proposal will delineate a new crosstalk between TLR2 and
tauopathy and describe if selective targeting of activated status of TLR2 by wtTIDM peptide reduces tangle
pathology, highlighting the discovery of a prospective intranasal agent to reduce tau pathology in AD, PSP,
FTD, and other tauopathies.
Administrative supplement: TLR2 is present in different cell types in the brain. For example, in the brain, in
addition to microglia, TLR2 is also expressed in neurons. Therefore, here, we will investigate the role of
neuronal and microglial TLR2 in tauopathy and wtTIDM peptide-mediated clearance of tauopathy and
improvement in cognitive behaviors in P301S transgenic mice.
有效减少脑实质聚集的tau蛋白有望减少发育和
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KALIPADA PAHAN其他文献
KALIPADA PAHAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KALIPADA PAHAN', 18)}}的其他基金
Muscle building supplement HMB for remyelination
用于髓鞘再生的增肌补充剂 HMB
- 批准号:
10442389 - 财政年份:2020
- 资助金额:
$ 15.7万 - 项目类别:
Muscle building supplement HMB for remyelination
用于髓鞘再生的增肌补充剂 HMB
- 批准号:
10202489 - 财政年份:2020
- 资助金额:
$ 15.7万 - 项目类别:
Muscle building supplement HMB for remyelination
用于髓鞘再生的增肌补充剂 HMB
- 批准号:
10281373 - 财政年份:2020
- 资助金额:
$ 15.7万 - 项目类别:
Muscle building supplement HMB for remyelination
用于髓鞘再生的增肌补充剂 HMB
- 批准号:
10654820 - 财政年份:2020
- 资助金额:
$ 15.7万 - 项目类别: